Scott G Filler
Los Angeles Biomedical Research Institute
United States of America
Dr. Filler's laboratory focuses on understanding the mechanisms by which the fungi Candida albicans and Aspergillus fumigatus invade and damage cells of hospitalized patients, causing infections that frequently prove fatal, even when employing current therapies. Fungal invasins— the first two of which have been identified by Dr. Filler’s lab—are key to the eventual development of target vaccines. Dr. Filler is a co-founder and scientific advisory board member of NovaDigm Therapeutics, Inc., a company affiliated with LA BioMed that seeks to develop a vaccine against Candida and Staph infections.
Vaccine against infections
Mouse model of oropharyngeal candidiasis. Nat Protoc. 2012
Divergent Targets of Candida albicans Biofilm Regulator Bcr1 In Vitro and In Vivo. Eukaryot Cell. 2012
Divergent Responses of Different Endothelial Cell Types to Infection with Candida albicans and Staphylococcus aureus. PLoS One. 2012